Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth - Dec 9, 2022
Mother and son jogging Mother and son jogging Mother and son jogging Mother and son jogging
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
  • Dividend increased by 8.5%
  • Reflects Abbott's longstanding commitment to sustainable growth and shareholder returns

ABBOTT PARK, Ill., Dec. 9, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an increase of 8.5%.

This marks the company's 51st consecutive year of dividend growth. It will be the 396th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2023, to shareholders of record at the close of business on Jan. 13, 2023.

Abbott is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 113,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

 

SOURCE Abbott

For further information: Abbott Media: Kate Dyer, 224-668-9965; Abbott Financial: Scott Leinenweber, 224-668-0791
true
accessibility

You are about to exit for another Abbott country or region specific website

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.


The website you have requested also may not be optimized for your specific screen size.

Do you wish to continue and exit this website?

accessibility

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.


The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit this website?